Mesoblast

Mesoblast Equity

The The Equity of Mesoblast (MSB.AX) as of Oct 5, 2026 is 568.41 M USD. In the previous year, The Equity was 597.44 M USD — a change of -4.86% (lower).

Equity

568.41 MUSD

YoY

-4.86%

Last updated:

In 2026, Mesoblast's equity was 568.41 M USD, a -4.86% increase from the 597.44 M USD equity in the previous year.

The Mesoblast Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
481.05 M USD
Jan 1, 2020
549.33 M USD
Jan 1, 2021
581.40 M USD
Jan 1, 2022
497.04 M USD
Jan 1, 2023
501.84 M USD
Jan 1, 2024
480.36 M USD
Jan 1, 2025
597.44 M USD
Jan 1, 2026
568.41 M USD
The Mesoblast Equity history
YEAREquityYoY
568.41 MUSD-4.86%
597.44 MUSD+24.38%
480.36 MUSD-4.28%
501.84 MUSD+0.96%
497.04 MUSD-14.51%
581.40 MUSD+5.84%
549.33 MUSD+14.19%
481.05 MUSD-11.90%
546.01 MUSD+5.66%
516.77 MUSD-2.16%
528.16 MUSD-13.33%
609.36 MUSD+6.58%
571.72 MUSD—
Access this data via the Eulerpool API

Mesoblast Stock analysis

What does Mesoblast do? Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Mesoblast's Equity

Mesoblast's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Mesoblast's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Mesoblast's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Mesoblast's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Mesoblast’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Mesoblast stock

The Equity of Mesoblast is 568.41 M USD in 2026.

The Equity of Mesoblast changed from 597.44 M USD to 568.41 M USD, representing a -4.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Mesoblast since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Mesoblast historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Mesoblast

All Key Metrics — Mesoblast